🔔 Hot off the press!
💡 In this study from Cedars-Sinai Medical Center and Johns Hopkins University we demonstrate how to quantify coronary artery plaque volumes from serial CCTA scans with high reproducibility.
A special thanks to @damini_dey#CCTA
https://t.co/VrLjK5M9tM
Intensive medical therapy usual care for reducing noncalcified coronary plaque in women who have INOCA, according to results of a serial imaging subanalysis of the WARRIOR trial. #SCCT2025@joellenell@damini_dey@ChinnaiyanMD@CardiacCTGuy
https://t.co/StY2MK3B4S
Honored to receive the Best Original Science Award at the #SCCT2025 for our paper on coronary plaque in women.
A special thank you to Professor Damini Dey for excellent mentoring. As always, science is team work and I am incredibly grateful to have such great colleagues.
🏆 SCCT Best Original Science Award goes to Dr. Joel Lenell, MD, PhD at the 20th Annual @Heart_SCCT Scientific Meeting! Supported by @CVRF_SoCal and @CVMGBevHills
His winning abstract:
“Intensive Medical Treatment Reduces Non-calcified Coronary Plaque in Women With Non-obstructive CAD”—powered by AI-enabled plaque analysis in the WARRIOR trial.
📖 Read more: https://t.co/z0YaGchhiP
#CardioTwitter #AIinMedicine #WIC #SCCT2025 #CVImaging #PreventiveCardiology #WARRIORtrial #CAD #HeartHealth @Cardiac_Wire@DanielKarlsberg@BudoffMd@Cleerlyhealth@RayDalio
Global Longitudinal Strain (GLS) is an independent marker of long-term risk in unselected ACS patients but GLS does not provide incremental information when LVEF is already known. Check out our latest publicstion: https://t.co/4ZxQC3rCSr
#echofirst
Asked #ChatGPT to write a tweet about critical appraisal. I even got hashtags. Try asking for an #echofirst report with a severe aortic stenosis and you’ll even get clinical guidance. https://t.co/zgVLKLgtiC
You have a new #AI partner @drjohnm
The rationale behind GRACE v2.0 in long-term risk prediction after ACS appear weak. Items like HR and BP at presentation are likely of no long-term significance, while excluded measures like LVEF & NTproBNP are. An opportunity to improve prediction? #ISRHT22
@f2harrell When studying added prognostic value of a new variable to a model, is there any setting where you think the C-Statistic provide a better understanding than the LR-test with comparison of Chi2?
https://t.co/94VVq0rMmu #ISRHT22
GLS proved to be an independent predictor of death & HF-hospitalization after ACS. The marginal improvement in Harrell’s C from GLS on top of LVEF and clinical data does however suggest a limited clinical application of GLS in this population. #ISRHT22
https://t.co/274v8F34CH
LVEF reported to the SWEDEHEART registry appears reliable. Discrimination between stages of reduced LVEF in clinical practice does however remain more challenging.
Check out our SWEDEHEART validation study. #ISRHT22
https://t.co/Hq8Jo5gaxI